Mirna Therapeutics said this week that it has received notices of allowance for US patent application claims related to the therapeutic use of several tumor-suppressor microRNAs.
“The allowed claims include methods for reducing cancer cell proliferation by introducing mimics of miR-192 or miR-215 into cancer cells,” the company said. “Additional claims are directed to the use of miR-192 and miR-215 for specifically reducing proliferation of breast, cervical, colon, or skin cancer cells, and to methods for reducing cancer cell viability and inducing apoptosis by introducing miR-192 mimics into lung cancer cells.”
Mirna also said that it has received notices of allowance from the US Patent and Trademark Office for claims related to administering miRNA combinations to inhibit prostate and liver cancer cell proliferation.
“The allowed claims describe the use of miR-124 in combination with miR-34a, let-7b, let-7c, or let-7g for inhibiting cancer cell proliferation,” it said. Additional claims are directed to uses of the miRNA combinations with specific liver and prostate carcinoma types and to specific pharmaceutical formulations of the miRNA combinations.”